title: Generation of therapeutic T-lymphocytes after in vivo tumor transfection with an allogeneic class I major histocompatibility complex gene.
abstract: In an effort to enhance the generation of tumor-reactive T-lymphocytes for adoptive immunotherapy, we examined the effects of in vivo transfection of an allogeneic major histocompatibility complex (MHC) class I gene (H-2Ks) of the poorly immunogenic B16BL6 (BL6) melanoma of H-2b origin. Cells from lymph nodes (LNs) draining these tumors after transfection were assessed in adoptive immunotherapy experiments for tumor reactivity after sequential activation with anti-CD3 monoclonal antibody (mAb) followed by culture in interleukin (IL)-2. H-2Ks lipofection of progressively growing BL6 subcutaneous tumors did not reduce tumorigenicity. However, in vivo lipofection of BL6 by intratumor inoculation or admixture of H-2Ks cDNA/liposome complexes and tumor cells prior to inoculation resulted in enhanced development of sensitized T-lymphocytes in the draining LN, which mediated the reduction of the numbers of established 3-day parental lung metastases in six of six experiments. In subsequent studies, in vivo transfection of BL6 with naked H-2Ks cDNA was found to be more effective than lipofection in eliciting sensitized T-cells in the draining LN. Admixture of liposomes alone or control plasmid DNA did not have an adjuvant effect similar to H-2Ks cDNA. Relative tumor transfection efficiency was assessed by an indirect assay with the chloramphenicol acetyltransferase (CAT) reporter gene. BL6 tumors were more efficiently transfected by intratumor inoculation with naked cDNA compared with lipofection. In summary, in vivo allogenization of the poorly immunogenic BL6 tumor resulted in enhanced generation of therapeutic T-cells effective in the treatment of parental tumor.
authors.affiliation: Department of Surgery, University of Michigan, Ann Arbor, USA.
authors.forename: W L
authors.initials: WL
authors.lastname: Wahl
authors.forename: S E
authors.initials: SE
authors.lastname: Strome
authors.forename: G J
authors.initials: GJ
authors.lastname: Nabel
authors.forename: G E
authors.initials: GE
authors.lastname: Plautz
authors.forename: M J
authors.initials: MJ
authors.lastname: Cameron
authors.forename: H
authors.initials: H
authors.lastname: San
authors.forename: B A
authors.initials: BA
authors.lastname: Fox
authors.forename: S
authors.initials: S
authors.lastname: Shu
authors.forename: A E
authors.initials: AE
authors.lastname: Chang
mesh_terms: D000276:Adjuvants, Immunologic; D000818:Animals; D005805:Genes, MHC Class I; D007111:Immunity, Cellular; D016219:Immunotherapy, Adoptive; D008081:Liposomes; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology*; D008546:Melanoma, Experimental / Q000235:genetics* / Q000556:secondary / Q000628:therapy; D051379:Mice; D008810:Mice, Inbred C57BL; D016176:T-Lymphocyte Subsets / Q000276:immunology*; D014162:Transfection / Q000276:immunology*; D014407:Tumor Cells, Cultured
chemical_list: D000276:Adjuvants, Immunologic; D008081:Liposomes